Helicobacter pylori is an important human pathogen that colonises the stomach of about half
of the world's population. The bacterium has now been accepted as the causative agent of …

Eradication therapy for Helicobacter pylori is recommended in a number of clinical
conditions. In this article, we discuss the epidemiology and cellular mechanisms that result …

nitrofurans (NFs) have been in clinical use for over 60 years. These affordable drugs are
used for the treatment of a broad spectrum of diseases ranging from urinary tract infections …

Helicobacter pylori infects approximately 50% of the world's population and is considered
the major etiological agent of severe gastric diseases, such as peptic ulcers and gastric …

Nitazoxanide (NTZ) is a redox-active nitrothiazolyl-salicylamide prodrug that kills
Helicobacter pylori and also many anaerobic bacterial, protozoan, and helminthic species …

Helicobacter pylori drug resistance presents a significant challenge to the successful
eradication of this pathogen. To find strategies to improve the eradication efficacy of H …

Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer
disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in …

Giardia lamblia and Entamoeba histolytica are amitochondriate, microaerophilic protists
which use fermentation enzymes like those of bacteria to survive anaerobic conditions within …

ABSTRACT Background and Aim. Failure of primary anti‐H. pylori therapy results in a high
rate of antimicrobial resistance. Here, we investigated the efficacy of high‐dose dual therapy …

The aim of this study was to evaluate Helicobacter pylori antibacterial resistance in 2005 to
2007, resistance evolution since 1996 to 1999, and performance of breakpoint susceptibility …